ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1561

The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate

Doo-Ho Lim1, Seokchan Hong2, Soo Min Ahn2, Byeongzu Ghang3, Wook Jang Seo4, Yong-Gil Kim1, Chang-Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 4Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic agents, Bisphosphonates, bone density and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Osteoporosis is more frequently observed in patients with rheumatoid arthritis (RA) than in general population. Bisphosphonate (BP), which suppresses bone resorption by inhibiting osteoclast activation, has been most commonly used for treatment of osteoporosis. Previous studies demonstrated that anti-TNF therapy has a beneficial effect on bone loss possibly through anti-inflammatory effects as well as its inhibitory effects on osteoclast activation. However, there have been few studies assessing the role of TNF blocker for osteoporosis in RA patients under concomitant treatment with BP. Therefore, we performed a retrospective longitudinal study to investigate the changes in bone loss in RA patients received BP with or without TNF blockers.

Methods:

The study cohort consisted of 107 RA patients who were diagnosed with osteoporosis and treated with BP, at a tertiary referral center from Jan. 2005 to Dec. 2013. The areal bone mineral density (BMD) (g/cm2) of the lumbar spine, femur neck, trochanter and total femur was measured by dual-energy X-ray absorptiometry. Follow-up BMD was obtained at 1.22 ± 0.36 years after initial acquisition of BMD. The rate of change in the BMD was expressed as the annualized percentage change of BMD between initial measurement and subsequent measurement.

Results:

Among RA patients receiving BP with (n = 19) and without TNF blockers (n = 88), 19 (100.0 %) and 80 (90.9 %) were women, respectively. The mean ages at initial BMD for these subjects were 67.4 ± 10.3 years (range, 46 – 84 years) and 66.1 ± 8.3 years (range, 43 – 83 years), respectively (P = 0.569). There was no significant difference in baseline clinical characteristics including laboratory data, baseline BMD and dose of corticosteroid between the two groups. With BP Treatment, follow-up BMD was significantly increased at the area of lumbar spine in RA patients regardless of concomitant use of TNF blockers. Further, there were no statistical significant differences in annualized BMD changes between RA patients receiving BP with or without TNF blockers, although there was a numerical difference in the BMD changes between the two groups (Table 1).

Conclusion:

In RA patients with osteoporosis receiving BP, there was a no significant additional effect of TNF blockers for bone loss. Therefore, administration of BP is still important in treatment of osteoporosis in patients with RA, even in those who were taking TNF blockers. 

Table 1. Comparison of mean annualized changes of BMD between patients with and without TNF-blockers

Annualized BMD changes (%/yr)

With TNF blockers

(n = 19)

Without TNF blockers

(n = 88)

p value

Lumbar spine

Neck of femur

Trochanter

Total of femur

4.11 ± 7.2

2.61 ± 8.5

3.45 ± 17.4

2.54 ± 10.2

2.61 ± 7.9

0.63 ± 7.9

-0.53 ± 9.8

-0.30 ± 5.9

0.450

0.328

0.173

0.103

BMD; Bone Mineral Density


Disclosure: D. H. Lim, None; S. Hong, None; S. M. Ahn, None; B. Ghang, None; W. J. Seo, None; Y. G. Kim, None; C. K. Lee, None; B. Yoo, None.

To cite this abstract in AMA style:

Lim DH, Hong S, Ahn SM, Ghang B, Seo WJ, Kim YG, Lee CK, Yoo B. The Effect of TNF Blockers on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-effect-of-tnf-blockers-on-bone-mineral-density-in-rheumatoid-arthritis-patients-receiving-bisphosphonate/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-tnf-blockers-on-bone-mineral-density-in-rheumatoid-arthritis-patients-receiving-bisphosphonate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology